

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-92) PATENT AND TRADEMARK OFFICE


ATTY. DOCKET NO.: 17620/9277

SERIAL NO.: 09/402,636

APPLICANT: Mazess *et al.*

FILING DATE: April 26, 2000

GROUP: 1644



INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT:

(Use several sheets if necessary)

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

P2H	AN	Holick, M., <i>et al.</i> , "Identification of 1,25-Dihydroxycholecalciferol, a Form of Vitamin D <sub>3</sub> Metabolically Active in the Intestine", <i>Proc. Nat. Acad. Sci. USA</i> , 68:803-804 (1971).
	AO	Holick, M., <i>et al.</i> , "1 $\alpha$ -Hydroxy Derivative of Vitamin D <sub>3</sub> : A Highly Potent Analog of 1 $\alpha$ ,25-Dihydroxyvitamin D <sub>3</sub> ", <i>Science</i> 180:190-191 (1973).
	AP	Jensen, G., <i>et al.</i> , "Treatment of Post Menopausal Osteoporosis. A Controlled Therapeutic Trial Comparing Oestrogen/Gestagen, 1,25-Dihydroxy-Vitamin D <sub>3</sub> and Calcium" <i>Clin. Endocrinol.</i> 16:515-524 (1982).
	AQ	Jones, G. <i>et al.</i> , "Isolation and Identification of 1,25-Dihydroxyvitamin D <sub>2</sub> ", <i>Biochemistry</i> , 14:1250-1256 (1975).
	AR	Köhler, G., <i>et al.</i> , "Continuous Cultures of Fused Cells Secreting Antibody Of Predefined Specificity", <i>Nature</i> 256:495-497 (1975).
	AS	Köhler, G., <i>et al.</i> "Derivation of Specific Antibody-Producing Tissue Culture And Tumor Lines by Cell Fusion", <i>Eur. J. Immunol.</i> 6:511-519. (1976).
	AT	Lam, H., <i>et al.</i> , "1 $\alpha$ -Hydroxyvitamin D <sub>2</sub> : A Potent Synthetic Analog of Vitamin D <sub>2</sub> ", <i>Science</i> 486:1038-1040 (1974).
	AU	Miller, G., <i>et al.</i> , "The Human Prostatic Carcinoma Cell Line LNCaP Expresses Biologically Active, Specific Receptors for 1 $\alpha$ ,25-Dihydroxyvitamin D <sub>3</sub> , <i>Cancer Res.</i> 52:515-520 (1992).
	AV	Orimo, H., <i>et al.</i> , "Reduced Occurrence of Vertebral Crush Fractures in Senile Osteoporosis Treated with 1 $\alpha$ (OH)-vitamin D <sub>3</sub> ", <i>Bone and Mineral</i> 3:47-52 (1987).
	AW	Ott, S., and Chesnut, C., "Calcitriol Treatment is Not Effective in Postmenopausal Osteoporosis", <i>Ann. Int. Med.</i> 110:267-274 (1989).
	AX	Ponpipom, M., <i>et al.</i> , "Saccharide Receptor-Mediated Drug Delivery", <i>Receptor-Mediated Targeting of Drugs</i> , (Gregoriadis <i>et al.</i> , ed.) NATO ASI series, 53-71 (1983).
	AY	Poznansky, M., <i>et al.</i> , "Biological Approaches to the Controlled Delivery of Drugs: A Critical Review", <i>Pharmacol. Rev.</i> 36:277-336 (1984).
	AZ	<u>Molecular Cloning</u> , 2nd ed., Sambrook <i>et al.</i> , eds., Cold Spring Harbor Lab. Press, 18.3 <i>et seq.</i> (1989).
	BA	Shiraki, M., <i>et al.</i> , "Long-Term Treatment of Postmenopausal Osteoporosis with Active Vitamin D <sub>3</sub> , 1-Alpha-Hydroxycholecalciferol (1 $\alpha$ -OHD <sub>3</sub> ) and 1,24 Dihydroxycholecalciferol (1,24(OH) <sub>2</sub> D <sub>3</sub> )", <i>Endocrinol. Japan</i> 32:305-315 (1985).
	BB	Skowronski, R., <i>et al.</i> , "Actions of Vitamin D <sub>3</sub> Analogs on Human Prostate Cancer Cell Lines: Comparison with 1,25-Dihydroxyvitamin D <sub>3</sub> ", <i>Endocrinology</i> 136:20-26 (1995).
✓	BC	Sørensen, O., <i>et al.</i> , "Treatment of Senile Osteoporosis with 1 $\alpha$ -Hydroxyvitamin D <sub>3</sub> ", <i>Clin. Endocrinol.</i> 7:169S-175S (1977).

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 17620/9277

SERIAL NO.: 09/402,636


INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT:

APPLICANT: Mazess *et al.*

(Use several sheets if necessary)

FILING DATE: April 26, 2000

GROUP: 1644



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PNH	AA	4,225,596	09-30-80	DeLuca, H. F.			
↓	AB	4,391,802	07-05-83	Suda, <i>et al.</i>			
↓	AC	5,183,815	02-02-93	Saari <i>et al.</i>			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
PNH	AD	0201-057-B1	12-02-92	EP			
↓	AE	0512-844-A1	11-11-92	EP			
↓	AF	2-104593	1990	JP			X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PNH	AG	Aloia, J., <i>et al.</i> , "Calcitriol in the Treatment of Postmenopausal Osteoporosis", <i>Amer. J. Med.</i> 84:401-408 (1988).
	AH	Baggiolini, E., <i>et al.</i> , "Stereocontrolled Total Synthesis of 1 $\alpha$ ,25-Dihydroxyergocalciferol", <i>J. Org. Chem.</i> , 51:3098-3108 (1986).
	AI	Brewster, M., <i>et al.</i> , "Improved Delivery through Biological Membranes. 32. <sup>1</sup> Synthesis and Biological Activity of Brain-Targeted Delivery Systems for Various Estradiol Derivatives", <i>J. Med. Chem.</i> 31: 244-249 (1988).
	AJ	Christiansen, C., <i>et al.</i> , "Effect of 1,25-dihydroxy-vitamin D <sub>3</sub> in Itself or Combined With Hormone Treatment In Preventing Postmenopausal Osteoporosis", <i>Eur. J. Clin. Invest.</i> 11: 305-309 (1981).
	AK	Counsell, R., <i>et al.</i> , "Lipoproteins as Potential Site-Specific Delivery Systems for Diagnostic and Therapeutic Agents", <i>J. Med. Chem.</i> 25:1115-1120 (1982).
	AL	Davis, S., <i>et al.</i> "Colloidal Delivery Systems-Opportunities and Challenges", <i>Site-Specific Drug Delivery</i> , (Tomlinson <i>et al.</i> eds.), John Wiley, New York, 93-111 (1986).
✓	AM	Gallagher, J, <i>et al.</i> , " Treatment of Postmenopausal Osteoporosis with High Doses of Synthetic Calcitriol", <i>Ann. Int. Med.</i> 113:649-655 (1990).

EXAMINER

DATE CONSIDERED

PNH N. Hys

4/11/01

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.